Skip to main content
20/11/2023

The diagnosis and treatment of prostate cancer are among the focuses of VHIR's research

Grup de Recerca Biomèdica en Urologia del VHIR

Grup de Recerca Biomèdica en Urologia del VHIR

Laboratori de Recerca Biomèdica en Urologia

Laboratori de Recerca Biomèdica en Urologia

Laboratori de Recerca Biomèdica en Urologia

Laboratori de Recerca Biomèdica en Urologia

20/11/2023

One more year, we join the Movember movement to raise awareness of the need for research to improve men's health and, in particular, that of patients with prostate cancer.

Among the main efforts of the Biomedical Research in Urology group at Vall d'Hebron Institute of Research (VHIR) is the study of prostate cancer. Once again, in November, we join the Movember movement to highlight the importance of research to improve men's health and, in particular, we present the most important research areas of the group to improve the diagnosis and treatment of prostate cancer.

In particular, the research group is made up of a team that includes professionals specialised in molecular biology, urology, oncology and pathology, who lead different projects in three fundamental research areas:

Use of Radiogenomics and Big Data and Artificial Intelligence Technologies

One of the most outstanding projects the team is working on is the TARTAGLIA project, which uses artificial intelligence to improve the early diagnosis of prostate cancer. To this end, clinical variables that are routinely used to diagnose the disease are being used to generate an algorithm that can accurately identify aggressive prostate tumours and differentiate them from those that are more benign.

In this sense, the group is also involved in a European project that uses artificial intelligence to improve the diagnosis of clinically significant prostate cancer, using a federated network involving different European centres.

The TARTAGLIA project is funded through the Artificial Intelligence R&D Missions Programme of the State Secretariat for Digitalisation and Artificial Intelligence (SEDIA) of the Ministry of Economic Affairs and Digital Transformation (File No. MIA.2021.M02.0005), corresponding to the funds of the Recovery, Resilience and Transformation Plan.

Improving diagnosis and management of patients with BRCA2 mutations

The team also focuses on prostate cancer patients with mutations in the BRCA2 gene. To do so, they explore the molecular alterations that contribute to the onset of the disease and study the mechanisms of resistance to current treatments in this group of patients. This approach is relevant to study new strategies to improve the diagnosis and management of patients with this type of mutation.

Study of Cell Division Regulators and Resistance to Hormone Therapy

On the other hand, the group investigates regulators of cell division involved in resistance to drugs with hormonal action, with the aim of developing new therapeutic agents for the treatment of more aggressive prostate tumours. Using ex vivo primary culture models and a large collection of liquid and tissue biopsies of prostate cancer, advances are being made in understanding the mechanisms of progression and resistance to therapy.

Related news

The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control.

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Related professionals

David Ruiz Casajuana

David Ruiz Casajuana

Research technician
Biomedical Research in Urology
Read more
Maria Carme Altadill Sanchez

Maria Carme Altadill Sanchez

Biomedical Research in Urology
Read more
Carlos Serrano Burgos

Carlos Serrano Burgos

Research assistant
Biomedical Research in Urology
Read more
Enric Miret Alomar

Enric Miret Alomar

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.